Nivolumab, a fully human IgG4 monoclonal antibody against programmed cell death protein 1 (PD-1), is an effective treatment for non-small cell lung cancer and melanoma, among other cancers [163]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.